Prediction of Coronary Artery Disease Severity by Epicardial Adipose Tissue Thickness
Predictive Value of Epicardial Fat Thickness for Disease Severity in Coronary Artery Disease Patients
1 other identifier
observational
200
1 country
1
Brief Summary
is to test the hypotheses that epicardial adipose tissue can be a marker of severity of coronary artery disease in myocardial infarction patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 6, 2017
CompletedFirst Posted
Study publicly available on registry
October 12, 2017
CompletedStudy Start
First participant enrolled
November 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2018
CompletedOctober 12, 2017
October 1, 2017
1 month
October 6, 2017
October 11, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
measurement of epicardial adipose tissue as marker of severity of coronary artery disease in myocardial infarction patients.
epicardial adipose tissue measurement using transthoracic echocardiography and cardiac magnetic resonance
one year
Study Arms (1)
myocardial infarction patients
transthoracic echocardiography and cardiac magnetic resonance
Interventions
transthoracic echocardiography and magnetic resonance imaging of the heart
Eligibility Criteria
acute myocardial infarction patiens not previously underwent percutaneous coronary angiography or coronary artery bypass grafting
You may qualify if:
- Normal thoracic shape
- Sinus rhythm
- without severe respiratory diseases
You may not qualify if:
- contraindication for cardiac magnetic resonance.
- Patients who previously underwent coronary artery bypass grafting or percutaneous coronary angiography prior to admission
- history of chronic kidney disease with glomerular filtration rate \<30 mL/min
- pericardial and/or pleural effusion.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Osama Fekrylead
Study Sites (1)
Jacqueline George
Asyut, Single, Egypt
Related Publications (1)
Desferrioxamine and transfusional iron overload. Lancet. 1978 Mar 4;1(8062):479-80. No abstract available.
PMID: 76025RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
October 6, 2017
First Posted
October 12, 2017
Study Start
November 1, 2017
Primary Completion
December 1, 2017
Study Completion
September 1, 2018
Last Updated
October 12, 2017
Record last verified: 2017-10